• Free shipping from $200
  • collecting affordable offers from best manufacturers worldwide
  • Special offers every week

Category: Press Releases

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer Distinguished Ophthalmic Leader to Support Ongoing Clinical Development of Lead Product EGP-437

WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Michael B. Raizman, MD as the Consulting Chief Medical Officer. Dr. Raizman began working with the…

Read More

Press Releases

EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced its financial results for the year ended December 31, 2014. Stephen From, President and CEO, stated,…

Read More

Press Releases

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

WALTHAM, Mass., May 16, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Steven Boyd has joined its board. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Steven Boyd to…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company will present at the upcoming H.C. Wainwright 20th Annual Global Investment Conference, being held on September 4-6, 2018 at the…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants

WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the pricing of an underwritten public offering of 1,176,470 shares of its common stock and…

Read More

Press Releases

EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that patient enrollment is complete in the next two pilot studies using the Hyaluronic Acid (HA) polymer for both photorefractive keratectomy (PRK)…

Read More

Press Releases

Eyegate Pharmaceuticals, Inc. Announces Closing of Initial Public Offering of Approximately $4,100,000 of Common Stock

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced initial public offering of 683,250 shares of its common stock at a price…

Read More

Press Releases

EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

WALTHAM, Mass., August 07, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s…

Read More

Press Releases

EyeGate Pharma to Present at Jefferies 2020 Virtual Healthcare Conference

WALTHAM, MA, June 1, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that its Chief Executive Officer, Stephen From, will be presenting at Jefferies Virtual Healthcare Conference, taking place from June 2-4, 2020. Presentation Details Date:…

Read More

Press Releases